This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsuno, F. Articles by Seon, B. K. Search for Related Content PubMed PubMed Citation Articles by Matsuno, F. Articles by Seon, B. K.

Induction of Lasting Complete Regression of Preformed Distinct Solid Tumors by Targeting the Tumor Vasculature Using Two New Anti-Endoglin Monoclonal Antibodies¹

Departments of Immunology [F. M., Y. H., M. K., H. T., B. K. S.] and Pathology [M. B.], Roswell Park Cancer Institute, Buffalo, New York 14263

ABSTRACT

Endoglin (EDG, CD105) is a proliferation-associated antigen on endothelial cells. In this study, two new anti-EDG monoclonal antibodies (mAbs) Y4-2F1 (or termed SN6j) and P3-2G8 (SN6k) were generated and used for treating distinct preformed tumors. These mAbs, both IgG1- antibodies, cross-reacted weakly with mouse endothelial cells but defined epitopes different from the epitope defined by a previously reported anti-EDG mAb K4-2C10 (B. K. Seon et al., Clin. Cancer Res., 3: 1031–1044, 1997). SN6j and SN6k reacted strongly with human endothelial cells and vascular endothelium of malignant human tissues but showed no significant reactivity with tumor cells per se. The deglycosylated ricin A chain (dgRA) conjugates of the two mAbs showed a weak but specific cytotoxic activity against murine endothelial cells in vitro.

In the therapeutic studies, severe combined immunodeficient mice were inoculated s.c. with MCF-7 human breast cancer cells and left untreated until palpable tumors of distinct size (4–6 mm in diameter) appeared. Mice with the distinct tumors were treated by i.v. administration of individual anti-EDG conjugates, unconjugated mAbs, or a control conjugate. Long-lasting complete regression of the tumors was induced in the majority of tumor-bearing mice (n = 8 for each conjugate) when 40 µg of the individual conjugates were administered three times via the tail vein. It is remarkable that the tumors remained regressed without further therapy for as long as the mice were followed (i.e., 100 days). Control conjugate did not induce regression of the tumors in any of the treated mice, although weak nonspecific effects were observed in some of the mice (n = 8). The effects of unconjugated mAbs were small with the dose used, i.e., 34 µg three times. The anti-EDG conjugates showed antiangiogenic activity in the dorsal air sac assay in mice. The results suggest good potential of these conjugates for the clinical application.

This article has been cited by other articles:

				N. A. Dallas, S. Samuel, L. Xia, F. Fan, M. J. Gray, S. J. Lim, and L. M. Ellis Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy Clin. Cancer Res., April 1, 2008; 14(7): 1931 - 1937. [Abstract] [Full Text] [PDF]

				G. Bellone, D. Solerio, L. Chiusa, G. Brondino, A. Carbone, A. Prati, T. Scirelli, M. Camandona, G. Palestro, and M. Dei Poli Transforming Growth Factor-{beta} Binding Receptor Endoglin (CD105) Expression in Esophageal Cancer and in Adjacent Nontumorous Esophagus as Prognostic Predictor of Recurrence Ann. Surg. Oncol., November 1, 2007; 14(11): 3232 - 3242. [Abstract] [Full Text] [PDF]

				R. L. Elliott and G. C. Blobe Role of Transforming Growth Factor Beta in Human Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2078 - 2093. [Abstract] [Full Text] [PDF]

				P. E. Thorpe Vascular Targeting Agents as Cancer Therapeutics Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427. [Abstract] [Full Text] [PDF]

				S. E. DUFF, C. LI, J. M. GARLAND, and S. KUMAR CD105 is important for angiogenesis: evidence and potential applications FASEB J, June 1, 2003; 17(9): 984 - 992. [Abstract] [Full Text] [PDF]

				D. A. Marchuk, S. Srinivasan, T. L. Squire, and J. S. Zawistowski Vascular morphogenesis: tales of two syndromes Hum. Mol. Genet., April 2, 2003; 12(90001): R97 - 112. [Abstract] [Full Text] [PDF]

				T. Sanchez-Elsner, L. M. Botella, B. Velasco, C. Langa, and C. Bernabeu Endoglin Expression Is Regulated by Transcriptional Cooperation between the Hypoxia and Transforming Growth Factor-beta Pathways J. Biol. Chem., November 8, 2002; 277(46): 43799 - 43808. [Abstract] [Full Text] [PDF]

				N. Takahashi, A. Haba, F. Matsuno, and B. K. Seon Antiangiogenic Therapy of Established Tumors in Human Skin/Severe Combined Immunodeficiency Mouse Chimeras by Anti-Endoglin (CD105) Monoclonal Antibodies, and Synergy between Anti-Endoglin Antibody and Cyclophosphamide Cancer Res., November 1, 2001; 61(21): 7846 - 7854. [Abstract] [Full Text] [PDF]

				F. Tanaka, Y. Otake, K. Yanagihara, Y. Kawano, R. Miyahara, M. Li, T. Yamada, N. Hanaoka, K. Inui, and H. Wada Evaluation of Angiogenesis in Non-small Cell Lung Cancer: Comparison between Anti-CD34 Antibody and Anti-CD105 Antibody Clin. Cancer Res., November 1, 2001; 7(11): 3410 - 3415. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Expresson of Vascular Endothelial Growth Factor, Its Receptors (FLT-1, KDR) and TSP-1 Related to Microvessel Density and Patient Outcome in Vertical Growth Phase Melanomas Am. J. Pathol., July 1, 2001; 159(1): 223 - 235. [Abstract] [Full Text] [PDF]

				N. Takahashi, R. Kawanishi-Tabata, A. Haba, M. Tabata, Y. Haruta, H. Tsai, and B. K. Seon Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and SuppressiveEffect of Chemotherapy on the Serum Endoglin Clin. Cancer Res., March 1, 2001; 7(3): 524 - 532. [Abstract] [Full Text]

				X. Ma, M. Labinaz, J. Goldstein, H. Miller, W. J. Keon, M. Letarte, and E. O'Brien Endoglin Is Overexpressed After Arterial Injury and Is Required for Transforming Growth Factor-{beta}-Induced Inhibition of Smooth Muscle Cell Migration Arterioscler. Thromb. Vasc. Biol., December 1, 2000; 20(12): 2546 - 2552. [Abstract] [Full Text] [PDF]

				A. W. Griffioen and G. Molema Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation Pharmacol. Rev., June 1, 2000; 52(2): 237 - 268. [Abstract] [Full Text] [PDF]

				E. Fonsatti, A. P. Jekunen, K. J. A. Kairemo, S. Coral, M. Snellman, M. R. Nicotra, P. G. Natali, M. Altomonte, and M. Maio Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model Clin. Cancer Res., May 1, 2000; 6(5): 2037 - 2043. [Abstract] [Full Text]

				C. LI, I. N. HAMPSON, L. HAMPSON, P. KUMAR, C. BERNABEU, and S. KUMAR CD105 antagonizes the inhibitory signaling of transforming growth factor {beta}1 on human vascular endothelial cells FASEB J, January 1, 2000; 14(1): 55 - 64. [Abstract] [Full Text]